Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ECT response prediction and rivastigmine for reducing cognitive side effects
NL-OMON60792Phase 4Completed
- Sponsor
- University Medical Center Groningen
- Start
- Sep 2021
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of rivastigmine in major depressive disorder (MDD) and bipolar disorder (BD), sponsored by University Medical Center Groningen. Primary endpoint: Cognitive and memory outcomes with rivastigmine versus placebo. Started Sep 2021; status: completed.
02
Drugs
rivastigmine
03
Conditions
major depressive disorder (MDD)bipolar disorder (BD)
Beyond the preview
Go deeper on NL-OMON60792.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60792.